Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis

详细信息    查看全文

• 作者：Lars Berglund ; M.D. ; Ph.D. ; FAHA^a ; ^b ; ^{lars.berglund@ucdmc.ucdavis.edu" class="auth_mail} (Professor) ; John D. Brunzell ; M.D.^c ; ¹ ; ^{JBrunzell@medicine.washington.edu" class="auth_mail} (Professor) ; Anne C. Goldberg ; M.D.^d ; ² ; ^{agoldber@dom.wustl.edu" class="auth_mail} (Professor) ; Ira J. Goldberg ; M.D.^e ; ³ ; ^{ijg3@columbia.edu" class="auth_mail} (Professor) ; Anton Stalenhoef ; M.D. ; Ph.D. ; FRCP^f ; ^{A.Stalenhoef@aig.umcn.nl" class="auth_mail} (Professor)
• 关键词：dyslipidemia ; lipoproteins ; coronary heart disease ; hypolipidemic therapy ; lifestyle intervention
• 刊名：Best Practice Research Clinical Endocrinology Metabolism
• 出版年：June 2014
• 年：2014
• 卷：28
• 期：3
• 页码：423-437
• 全文大小：306 K

文摘

While there has been considerable focus on the role and treatment of LDL cholesterol levels, a definitive role of triglycerides in the management of cardiovascular disease has been uncertain. Notably, with increasing triglyceride levels, there is a parallel increase in cholesterol levels carried by triglyceride-rich lipoproteins, which has prompted interest in the use of non-HDL cholesterol levels as a tool guiding interventions. Recent studies have provided evidence for an independent role of triglyceride levels as a cardiovascular risk factor, and recently, an Endocrine Society guideline was published for treatment of hypertriglyceridemia. In contrast to the relative uncertainty regarding triglycerides and cardiovascular disease, a role of very high triglyceride levels as a risk factor for pancreatitis has been well known. The present paper summarizes the underlying evidence for a risk role for triglyceride levels in cardiovascular disease and pancreatitis, current treatment recommendations and areas of future research.